Related Experiment Video
Updated: Mar 8, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone
1Department of Radiotherapy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, Shandong, China.
Background:
Triple-negative breast cancer (TNBC) with bone metastasis is associated with poor prognosis and limited treatment options. Denosumab has shown efficacy in preventing skeletal-related events, while PARP inhibitors have demonstrated promising activity in patients with homologous recombination deficiency.
Case:
We report a patient with TNBC and bone metastasis who received a combination treatment including denosumab, PARP inhibitors, and chemoradiotherapy. The treatment resulted in effective disease control and improvement of clinical symptoms. Imaging evaluation showed stabilization of bone lesions, and the patient tolerated the treatment well without severe adverse events.
Conclusion:
This case suggests that the combination of denosumab with PARP inhibitors and chemoradiotherapy may provide a potential therapeutic strategy for TNBC patients with bone metastasis. Further studies are warranted to validate the efficacy and safety of this combined treatment approach.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...